AIP
RUBY

Ameritas Investment Partners’s Rubius Therapeutics, Inc RUBY Stock Holding History

Ameritas Investment Partners’s Portfolio RUBY Stock Details RUBY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-3,535
Closed -$19K – 3334
2022
Q1 		$19K Hold
3,535
– – ﹤0.01% 2595
2021
Q4 		$34K Hold
3,535
– – ﹤0.01% 2380
2021
Q3 		$63K Hold
3,535
– – ﹤0.01% 2007
2021
Q2 		$86K Buy
3,535
+724
+26% +$18.1K ﹤0.01% 1825
2021
Q1 		$74K Hold
2,811
– – ﹤0.01% 1844
2020
Q4 		$21K Hold
2,811
– – ﹤0.01% 2458
2020
Q3 		$14K Hold
2,811
– – ﹤0.01% 2577
2020
Q2 		$17K Hold
2,811
– – ﹤0.01% 2447
2020
Q1 		$13K Hold
2,811
– – ﹤0.01% 2419
2019
Q4 		$27K Hold
2,811
– – ﹤0.01% 2267
2019
Q3 		$22K Hold
2,811
– – ﹤0.01% 2348
2019
Q2 		$44K Hold
2,811
– – ﹤0.01% 1997
2019
Q1 		$51K Buy
2,811
+1,808
+180% +$27.7K ﹤0.01% 1875
2018
Q4 		$16K Hold
1,003
– – ﹤0.01% 2472
2018
Q3 		$24K Buy
+1,003
New +$22.9K ﹤0.01% 2428

Other funds holding RUBY

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AFM
Abbot Financial Management Andover, Massachusetts $239M AUM 27.19% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Ameritas Investment Partners's RUBY Position: Q2 2022 in Review

Ameritas Investment Partners sold out of Rubius Therapeutics, Inc (RUBY) in Q2 2022, closing a stake of 3,535 shares — an estimated $19K sold.

Ameritas Investment Partners first reported a position in RUBY in Q3 2018 and held it in 15 quarters. The position peaked at $86K in Q2 2021. 72 funds tracked by Wall St. Rank hold RUBY as of Q2 2022.

  • Ameritas Investment Partners reported no remaining Rubius Therapeutics, Inc position as of Q2 2022 after selling out during the quarter.
  • Ameritas Investment Partners sold 3,535 Rubius Therapeutics, Inc shares in Q2 2022, an estimated $19K.
  • Ameritas Investment Partners first reported a position in Rubius Therapeutics, Inc in Q3 2018 and held it in 15 quarters.
  • Ameritas Investment Partners's Rubius Therapeutics, Inc position peaked at $86K in Q2 2021.
  • 72 funds tracked by Wall St. Rank held Rubius Therapeutics, Inc as of Q2 2022.

Based on Ameritas Investment Partners's 13F filing for Q2 2022, filed 12 Aug 2022.